News | June 30, 2022
Dr. Reddy's Laboratories announces conclusion of patent litigation with Indivior
The settlement and dismissal resolves all claims between the parties
The settlement and dismissal resolves all claims between the parties
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
HIL has set up the Bti bio-larvicide manufacturing facility at its Rasayani Plant at Maharashtra with the financial assistance of GEF/UNIDO under the project
First and only PARP inhibitor to improve invasive disease-free survival in patients
The Congress was held on June, 20-21, 2022 in Berlin, Germany
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.
It´s the first trial to demonstrate the benefits of dual pathway inhibition
Subscribe To Our Newsletter & Stay Updated
